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to-mesenchymal transition in
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Frank T Kolligs
Epithelial-to-mesenchymal transition (EMT)
is a reversible programme which allows
the transition between the epithelial and
the mesenchymal phenotype in embry-
onic development, the differentiation of
tissues and organs and tissue repair.1 A
direct link between EMT and epithelial
stem cell properties has been demon-
strated.2 Aberrant activation of EMT is
a trigger for organ fibrosis and the
progression and metastasis of epithelial
cancers.1 In colorectal cancer, EMT occurs
at the invasive front of the tumour and
results in the generation of single migra-
tory cells which have lost expression of
the adherens junction protein E-cadherin
and have gained expression of both
vimentin and fibronectin at the same
time. Additionally, these cells show acti-
vation of the Wnt signalling pathway.3 At
the histopathological level, tumour
buddingdthe detachment of tumour cells
from the main tumourdhas been
described to be closely related to EMTand
has been found to be an adverse prog-
nostic factor.4 Depending on tissue and
cell type, EMT is activated by several key
pathways, including TGF (transforming
growth factor) b, Notch and FGF (fibro-
blast growth factor) signalling which
converge in the stimulation of a group of
transcription factors repressing epithelial
gene expression.5
The gene EIF5A2 encodes the eukaryotic
initiation factor 5A2 and is located on
chromosome 3q26, a region frequently
amplified in several tumours.6 EIF5A2 has
been shown to induce anchorage-inde-
pendent growth and xenograft tumour
growth of ovarian cancer cells and to
enhance cancer cell migration and inva-
sion in cells derived from hepatocellular
carcinomas.7 8 In hepatocellular carci-
noma, EIF5A2 has been found to induce
EMT and to stimulate rearrangement of
the cytoskeleton through activation of
RhoA and Rac1.8 In their paper published
in Gut, Zhu et al report on the expression
and function of EIF5A2 in colorectal
cancer.9 EIF5A2 is reported to be overex-
pressed in 102 of 229 primary colorectal
cancers, and overexpression of EIF5A2 is
found to be an adverse prognostic factor.
The mean survival of patients with
tumours overexpressing EIF5A2 is
64.1 months compared to 83.3 months in
patients with tumours expressing normal
levels of EIF5A2. Moreover, EIF5A2 was
found to be strongly associated with
metastatic disease. In experimental
studies, the causal role of EIF5A2 in the
metastatic potential of colorectal cancer
cells was further explored. In colorectal
cancer cell lines, EIF5A2 was found to
enhance cell motility, invasion and
metastasis. In contrast to hepatoma cells
this was not mediated by Rho/Rac
GTPase activation. By PCR array, among
others, the E-cadherin interacting protein
a-catenin (CTNNA1) was found to be
negatively regulated and the metastasis-
associated protein 1 (MTA1) was found to
be positively regulated by EIF5A2. At the
tumour level, a strong association
between EIF5A2 expression with MTA1
expression but not with a-catenin
expression was found. Subsequent studies
showed that EIF5A2’s function to induce
invasiveness and EMTand its capability to
regulate EMT-associated markers such as
E-cadherin, vimentin and fibronectin in
colorectal cancer cells was dependent on
MTA1. Finally, it could be demonstrated
that c-MYC, a known regulator of MTA1,
was required for EIF5A2 regulating MTA1
expression. In conclusion, Zhu et al
present a rich body of evidence suggesting
that EIF5A2 might represent an important
factor regulating EMT in colorectal cancer
cells via the c-MYC dependent expression
of MTA1.
A hallmark of EMT is the loss of
expression of E-cadherin encoded by
CDH1, a crucial suppressor of cancer
invasion and progression. The character-
isation of E-cadherin regulation during
cancer progression has led to the
identification of E-cadherin repressors
which can be classified into two groups
depending on their effects on the CDH1
promoter1: the zinc finger transcriptional
repressors SNAI1 and SNAI2 (also known
as Snail and Slug, respectively), the zinc-
finger enhancer binding protein family
members ZEB1 and ZEB2, KLF (Krüppel-
like factor) 8, and the basic helix-loop-
helix (bHLH) factor E47 bind to and
repress the activity of the CDH1 promoter
directly; while Goosecoid, FoxC2 and the
bHLH factors Twist and E2-2 repress the
expression of E-cadherin indirectly. In
addition, c-MYC has been described to
indirectly drive the expression of SNAI1.10
As EIF5A2 is not a direct regulator of E-
cadherin, it remains to be established
whether EIF5A2’s function to repress E-
cadherin expression and to induce EMT is
mediated via MTA1 only or whether other
additional factors are involved. Interest-
ingly, another member of the family of
metastasis-associated genes, MTA3, has
been found to be a repressor of SNAI1
expression, resulting in the expression of
E-cadherin and preservation of the
epithelial phenotype, suggesting opposite
functions of different MTA family
members in the regulation of EMT-asso-
ciated genes and EMT.11 12 However,
a direct regulation of SNAI1 or another
known E-cadherin repressor and master
regulator of EMT by MTA1 has not been
demonstrated so far.
MTA1 is an integral component of the
Mi-2/nucleosome remodelling and histone
deacetylation (NuRD) complex and has
been shown to be a direct target of
c-MYC.13 It is a critical regulator of the
metastatic potential of tumour cells14 and
has been found to be indispensable for
c-MYC induced transformation and
EMT.13 Moreover, MTA1 expression has
also been associated with HIF-1a medi-
ated angiogenesis and has been proposed
as a master co-regulator of carcinogenesis
and progression of tumours.12 In the
presence of p53, MTA1 regulates genes
involved in antimicrobial and inflamma-
tory response, as well as carbohydrate
metabolism, while genes regulated by
MTA1 in the absence of p53 are predom-
inantly related to cancer signalling,
including direct and indirect interactions
with KRAS, epidermal growth factor
receptor (EGFR) and vascular endothelial
growth factor (VEGF) signalling.15 Recent
data indicate that TGF-b1 induces EMT
via stimulating the expression of MTA1.16
What are the implications of this
study? Activation of invasive and metas-
tasis-promoting capabilities and resistance
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to cell death are hallmarks of cancer cells
and characteristics of EMT.17 E-cadherin is
the key suppressor of motility and inva-
siveness in neoplastic epithelial cells.
Several transcription factors belonging
to different pathways repress the expres-
sion of E-cadherin and appear able to
orchestrate many steps of the inva-
sionemetastasis cascade. As our picture of
this complex and prognosis-determining
step is incomplete, the identification of
the role of EIF5A2 as an upstream regu-
lator of EMT and metastasis and the
description of the EIF5A2-MTA/c-MYC-
axis in EMT are important steps forward
(figure 1). The further understanding of
the network of factors regulating EMT
will ultimately allow the development of
new pathogenesis-directed preventive and
therapeutic approaches. As the expression
of EIF5A2 is deregulated in colorectal
cancer and is located upstream of MTA1,
EIF5A2 may serve as an interesting target
for anticancer therapy. However, further
understanding of the diverse roles of
MTA family members in homeostasis and
disease is required to understand the
overall consequences of such an approach.
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Too much fat for the gut’s
microbiota
Herbert Tilg,1 Julian R Marchesi2
The gastrointestinal tract contains
a diverse microbial community which is
predominantly bacterial and which we
refer to as the gut microbiota. For example,
the human gut microbiota is assumed to
consist of at least 1014 bacteria, composed
of more than 1000 species with more than
150 species per individual. Apart from
contributing substantial beneficial func-
tions to the host (eg, digestion of indi-
gestible plant polysaccharides and
production of short chain fatty acids), the
potential of the microbiota to interact
with the host and modulate its physiology
seems to be tremendous. In addition,
many ‘environmental’ and not yet identi-
fied factors might be able to affect
and modulate the gut’s microbial compo-
sition and functions, with implications for
the host.
Recent evidence has linked the develop-
ment of metabolic dysfunction with our
bacteriota, and studies in animals have
alluded to the fact that certain microbiotal
factors may be associated with the devel-
opment of diabetes.1 Whether metabolic
dysfunction might potentially lead to or be
preceded by a change in the microbiota
has not yet been determined. However, in
their paper published in Gut, Serino and
colleagues2 address this issue by using
a mouse model where C57Bl/6 mice with
the same genetic background on an iden-
tical fat-enriched carbohydrate-free diet
develop either diabetes or remain diabetes-
resistant.3 The development of diabetes
which appeared in a subgroup of mice was
strongly associated with a change in the
composition of the gut microbiota.2 Devel-
opment of diabetes was associated with
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Figure 1 EIF5A2 regulates epithelial-to-mesenchymal transition up-stream of MTA1 in colorectal
cancer cells. The regulation of MTA1 expression by EIF5A2 is partly dependent on c-MYC. c-MYC is
a known indirect regulator of the E-cadherin repressor SNAI1.
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